To: RNS
Date: 7 December 2022
Company: Target Healthcare REIT plc
LEI: 213800RXPY9WULUSBC04
Subject: Directorate Change
Directorate Change
The Board of Directors of Target Healthcare REIT plc ('the Company') is pleased to announce the appointment of Mr Michael Brodtman as an independent non-executive Director of the Company with effect from 1 January 2023.
Mr Brodtman has extensive knowledge of the property sector. He worked for global property advisers CBRE for over 40 years, retiring as chairman of the UK Advisory division in June 2022. He led the firm's Valuation department for over 20 years, and served on its Executive Board and Operating Committee, respectively responsible for strategic direction and day-to-day management.
He is a Fellow of the Royal Institution of Chartered Surveyors and has been extensively involved with the RICS throughout his professional career. He was formerly a member of the Policy Committee of the British Property Federation, the RICS Global Valuation Professional Board and the Bank of England Commercial Property Forum.
Mr Brodtman will also become a non-executive Director of Grainger plc with effect from 1 January 2023 and has further Board experience as a former non-executive director of Investment Property Databank and housing association Places for People. He is keenly interested in the healthcare sector, with relevant experience from his role as a Trustee of Jewish Care, which provides health and social care services for London's Jewish Community, including ten care homes with some 500 residents.
At the date of his appointment, Mr Brodtman holds 24,210 Ordinary Shares in the Company.
There is no further information required to be disclosed pursuant to paragraph 9.6.13 R of the Listing Rules in relation to this appointment.
All Enquiries:
Kenneth MacKenzie, Gordon Bland
Target Fund Managers Limited
01786 845 912
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.